Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 4Phase 2/3 2Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 15OTHER 8NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Mesothelioma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 7Radiotherapy 6Vincristine 5Etoposide 5Cyclophosphamide 5Cisplatin 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Doxorubicin 4Carboplatin 4Capecitabine 4pembrolizumab 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Prednisone 3Oxaliplatin 3Methotrexate 3Leucovorin 3Fluorouracil 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Surgical Procedures, Operative 2Ramucirumab 2Radiation 2Pemetrexed 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × NETWORK × Pemetrexed × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2/3 Completed
520 enrolled 16 charts 1 FDA
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡